Industry News

• Baxter receives marketing authorization for HyQvia in European Union  Baxter International and Halozyme Therapeutics announced the European Commission has granted Baxter marketing authorization in all EU Member States for the use of HyQvia (solution for subcutaneous use) as replacement therapy for adult patients with primary and secondary immunodeficiencies.
  May 21, 2013  
• Gold nanoparticles can help fight ovarian cancer  Positively charged gold nanoparticles are usually toxic to cells, but cancer cells somehow manage to avoid nanoparticle toxicity. Mayo Clinic researchers determined how to make the nanoparticles effective against ovarian cancer cells. The discovery is detailed in the Journal of Biological Chemistry.
  May 21, 2013  
• Largest-ever survey of women reveals women with advanced breast cancer feel left out  A new global survey sponsored by Novartis Oncology of nearly 1,300 women in 12 countries finds that despite breast cancer being the most common cancer in women worldwide, women living with advanced or metastatic breast cancer feel isolated and left out of the broader breast cancer movement.
  May 21, 2013  
• No-treatment approach may be best for older prostate cancer patients  Older prostate cancer patients with other underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by researchers in the UCLA Department of Urology.
  May 20, 2013  
• Hanger patient among first in world to receive bionic hand controlled by smart device  Recently, 48-year-old Scituate resident Mike Benning became one of the first people in the world to receive the i-limb ultra revolution, the newest bionic hand available. The i-limb ultra revolution is the first upper limb prosthesis that can be controlled via a mobile application.
  May 20, 2013  
• Zogenix and Battelle present positive data demonstrating value of needle-free injection  Zogenix and Battelle announced new data supporting the value of the DosePro® needle-free injection technology in delivery of biologics. The positive, new data show that the DosePro technology is compatible with monoclonal antibodies formulations and a range of biologic formulation viscosities.
  May 20, 2013  
• Inflammatory bowel disease raises risk of melanoma  Patients with inflammatory bowel disease are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent greater risk for the disease.
  May 20, 2013  
• German Federal Joint Committee issues final assessment report for PIXUVRI®  Cell Therapeutics reported that Germany's Federal Joint Committee has issued its final benefit assessment report for PIXUVRI® (pixantrone). The G-BA reported that additional benefit could not be determined for PIXVURI versus the comparator therapies assigned by G-BA.
  May 20, 2013  
• Intercept Pharmaceuticals announces positive initial results from ongoing phase 2a trial  Intercept announced positive initial results from OBADIAH, an ongoing Phase 2a trial of obeticholic acid (OCA) as treatment for primary bile acid diarrhea. Initial results demonstrate treatment with OCA is associated with statistically significant increased levels of fibroblast growth factor 19.
  May 20, 2013  
• ACADIA Pharmaceuticals added to NASDAQ Biotechnology Index  ACADIA Pharmaceuticals, a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced it has been selected for addition to the NASDAQ Biotechnology Index.
  May 20, 2013  

   (next 10 articles)